Verrica Pharmaceuticals Inc (OQ:VRCA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 10 N High St Ste 200
WEST CHESTER PA 19380-3014
Tel: N/A
Website: https://verrica.com
IR: See website
<
Key People
Ted W. White
President, Chief Executive Officer, Director
P. Terence Kohler
Chief Financial Officer
Christopher G. Hayes
General Counsel, Company Secretary, Chief Legal Office
Joe Bonaccorso
Chief Commercial Officer
Gary Goldenberg
Chief Medical Officer
 
Business Overview
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Financial Overview
For the fiscal year ended 31 December 2023, Verrica Pharmaceuticals Inc revenues decreased 43% to $5.1M. Net loss increased from $24.5M to $67M. Revenues reflect Collaboration revenue decrease of 95% to $466K. Higher net loss reflects General and administrative - Balancing increase from $13.9M to $32M (expense), Stock-Based Compensation in SG&A increase from $3.5M to $11.8M (expense).
Employees: 100 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $274.20M as of Dec 31, 2023
Annual revenue (TTM): $5.12M as of Dec 31, 2023
EBITDA (TTM): -$62.67M as of Dec 31, 2023
Net annual income (TTM): -$67.00M as of Dec 31, 2023
Free cash flow (TTM): -$38.94M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 42,418,553 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.